![](https://qtxasset.com/quartz/qcloud5/media/image/Asia%20Skyline.jpg?VersionId=D1z8mhSGFGZGeIyVQRyF2XVT.Or1FpKP)
Fierce Pharma Asia—Hengrui's FDA reprimands; Sanofi's India site expansion; Aslan's downfall
A 10-page Form 483 has detailed the shortfalls at Hengrui Pharma's PD-1 plant behind a recent FDA rejection. Sanofi is investing heavily to expand its global capacity center in India. Singapore biotech Aslan Pharma is winding down. And more. 1. Behind …